Stephens Investment Management Group LLC Has $21.64 Million Stock Holdings in Azenta, Inc. $AZTA

Stephens Investment Management Group LLC trimmed its stake in shares of Azenta, Inc. (NASDAQ:AZTA) by 4.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,024,048 shares of the company’s stock after selling 47,991 shares during the quarter. Stephens Investment Management Group LLC owned about 2.22% of Azenta worth $21,638,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Azenta by 2,067.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock worth $27,000 after buying an additional 765 shares during the period. Assetmark Inc. raised its holdings in Azenta by 54.1% in the 4th quarter. Assetmark Inc. now owns 832 shares of the company’s stock valued at $28,000 after acquiring an additional 292 shares during the period. Osaic Holdings Inc. lifted its position in Azenta by 44.9% during the second quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after acquiring an additional 385 shares during the last quarter. Rockefeller Capital Management L.P. boosted its holdings in shares of Azenta by 98.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock worth $46,000 after acquiring an additional 689 shares during the period. Finally, Van ECK Associates Corp grew its position in shares of Azenta by 141.2% in the fourth quarter. Van ECK Associates Corp now owns 1,585 shares of the company’s stock valued at $53,000 after purchasing an additional 928 shares during the last quarter. 99.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AZTA has been the subject of several research reports. Weiss Ratings cut Azenta from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 29th. Needham & Company LLC lowered their price objective on Azenta from $44.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $39.50.

Azenta Price Performance

Shares of NASDAQ:AZTA opened at $25.84 on Monday. Azenta, Inc. has a 12-month low of $15.93 and a 12-month high of $41.73. The company’s 50 day moving average price is $22.11 and its two-hundred day moving average price is $26.91. The firm has a market cap of $1.19 billion, a PE ratio of -6.53 and a beta of 1.37.

Azenta (NASDAQ:AZTA) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.16). The business had revenue of $144.79 million during the quarter, compared to analyst estimates of $148.47 million. Azenta had a negative net margin of 30.49% and a positive return on equity of 1.23%. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.01 earnings per share.

Azenta Company Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.